Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmazie ; 63(12): 893-8, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19177906

ABSTRACT

The anti-inflammatory activity of inhaled glucocorticoids is primarily mediated through transrepression of pro-inflammatory transcription factors such as AP-1 and NF-kappaB, while systemic side effects are largely attributed to transactivation via glucocorticoid response elements (GRE) in the promoter region of responsive genes. The objective of this study is to investigate whether inhaled corticosteroids exhibit differences in their transactivation and transrepression potencies. A549 human alveolar epithelial type II like cells, stably transfected with a reporter plasmid containing an AP-1, NF-kappaB or GRE induced secreted alkaline phosphatase reporter gene (SEAP), were exposed to a panel of concentrations of the six inhaled and three systemic glucocorticoids. Glucocorticoid-induced changes in SEAP expression were quantified by chemiluminescence. For eight glucocorticoids (budesonide, desisobutyryl-cicle-sonide, dexamethasone, flunisolide, fluocortolone, fluticasone propionate, mometasone furoate, prednisolone) the EC50 for NF-kappaB mediated transrepression was significantly larger than that for both transactivation and transrepression via AP-1. For the remaining glucocorticoid (triamcinolone acetonide), it was greater than that for transactivation. It is concluded that, within the studied cell system, inhaled corticosteroids did not exhibit preferential transrepression, but had higher potencies for transactivation than for transrepression via NF-kappaB and had differential potencies for the two transrepression pathways.


Subject(s)
Glucocorticoids/pharmacology , Transcriptional Activation/drug effects , Administration, Inhalation , Algorithms , Cell Line , Epithelial Cells/drug effects , Genes, Reporter/drug effects , Glucocorticoids/administration & dosage , Humans , NF-kappa B/genetics , Plasmids/drug effects , Plasmids/genetics , Response Elements/genetics , Transcription Factor AP-1/genetics , Transfection
2.
Int J Clin Pharmacol Ther ; 42(12): 701-18, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15624287

ABSTRACT

Despite recent advancements in solid organ transplantation, African-American renal allograft recipients continue to exhibit poorer prognosis in long-term clinical outcome and graft survival compared to Caucasian patients. The role of immunosuppressants in post-transplant outcome is crucial, and associations between exposure-related pharmacokinetic parameters and clinical outcome have been made for several drugs in this class. Thus, ethnic differences in the pharmacokinetics of immunosuppressants are potentially a key factor in the observed differences in post-transplant outcome between African-Americans and Caucasians. Ethnic differences in pharmacokinetics of mycophenolate mofetil and azathioprine based on the current literature are either absent or only of minor relevance. Cyclosporine, tacrolimus, sirolimus and everolimus, however, have all been described to exhibit ethnicity-specific differences in bioavailability and/or dose-adjusted systemic exposure, although currently available reports are controversial for some of these drugs. Oral bioavailability of these drugs in African-Americans was between 20 and 50% lower than in Caucasians or Non-African-Americans, leading to higher dose requirements in African-Americans to maintain similar average concentrations of the respective immunosuppressant. Since all four drugs undergo extensive metabolism and are substrates for CYP3A isoenzymes as well as the drug transporter P-glycoprotein, interethnic variability in activity of these enzymes/transporter may provide a common mechanism for the observed ethnic differences. These ethnic differences are most likely mediated via several non-genetic as well as genetic factors, including known genetic variations that impair transporter/enzyme activity in genes such as CYP3A4, CYP3A5 and ABCB1 (MDR1). Appreciation of differences in immunosuppressant pharmacokinetics and dose requirements between African-Americans and Caucasians in clinical practice is expected to improve post-transplant immunosuppressive pharmacotherapy and may thus contribute to equalize prognostic outcome for all transplant patients.


Subject(s)
Black People , Immunosuppressive Agents/pharmacokinetics , Mycophenolic Acid/analogs & derivatives , Sirolimus/analogs & derivatives , White People , Azathioprine/pharmacokinetics , Cyclosporine/pharmacokinetics , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Everolimus , Graft Survival , Humans , Mycophenolic Acid/pharmacokinetics , Organ Transplantation/ethnology , Randomized Controlled Trials as Topic , Sirolimus/pharmacokinetics , Tacrolimus/pharmacokinetics
3.
Appl Opt ; 8(2): 363-6, 1969 Feb 01.
Article in English | MEDLINE | ID: mdl-20072228

ABSTRACT

Experimental data comparing peak emission wavelength with organic dye laser cell length are presented. These data and knowledge of the variation of peak emission wavelength with organic dye concentration make reasonable the hypothesis that the observed effects are caused by self-absorption. A simple theory is developed on this hypothesis and the results of numerical calculations compared with the experimental data. Good agreement is obtained, but some departures from agreement suggest improvement may be expected from a time-dependent theory.

SELECTION OF CITATIONS
SEARCH DETAIL
...